Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has recently announced the breakthrough study achieved in collaboration with a well-known university in Hong Kong.

The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science.

No specific initiatives on AI in healthcare are in sight but the inevitable impact of this technology will guide EU policymaking in the next five years, according to Commissioner Olivér Várhelyi. View

By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential medicines than ever.

The AI-designed proteins neutralized lethal 3FTx toxins found in snake venom, which are often the reason that traditional antivenoms fail.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set

The U.S. Commerce Department is imposing new export controls on biotechnology equipment due to national security concerns linked to AI. The controls target technology that could aid China's military.

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where SoundHound AI, Inc. (NASDAQ:SOUN) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect,

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where SES AI Corporation (NYSE:SES) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect,

AI is merely one facet of a sweeping technological change underway, and companies that fail to recognize the importance of other converging technologies risk being left behind. Two other technologies — advanced sensors and biotechnology — are less visible,

Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology company known for its focus on RNA-targeted drug discovery and development.